NEW YORK, Jan. 31, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on AAAP, AMAG, DBVT, and IDXX which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, January 30, 2018, US markets saw broad based losses
Advanced Accelerator Applications
On Tuesday, shares in Advanced Accelerator Applications S.A. recorded a trading volume of 17,797 shares. The stock ended the session 0.13% higher at $82.12. The Company's shares have gained 12.63% over the previous three months and 160.78% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.61% and 42.00%, respectively. Moreover, shares of the Company, which develops, produces and sells molecular nuclear medicine, diagnostic and therapeutic products, have a Relative Strength Index (RSI) of 59.35. Get the full research report on AAAP for free by clicking below at: www.wallstequities.com/registration/?symbol=AAAP
Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc.'s stock closed the day 1.03% lower at $14.45 with a total trading volume of 961,621 shares, which was above their three months average volume of 837.69 thousand shares. The Company's shares have advanced 7.43% in the past month. The stock is trading above its 50-day moving average by 1.79%. Additionally, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have an RSI of 52.25. Free research on AMAG can be accessed at: www.wallstequities.com/registration/?symbol=AMAG
Shares in Bagneux, France-based DBV Technologies S.A. recorded a trading volume of 155,059 shares. The stock ended yesterday's trading session 4.75% lower at $23.45. The stock is trading below its 50-day moving average by 2.11%. Furthermore, shares of DBV Technologies, which engages in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children, have an RSI of 38.50. Sign up today for the free research report on DBVT at: www.wallstequities.com/registration/?symbol=DBVT
Westbrook, Maine headquartered IDEXX Laboratories Inc.'s stock finished Tuesday's session 0.10% lower at $186.59 with a total trading volume of 478,296 shares. The Company's shares have advanced 17.51% in the last month, 10.82% over the previous three months, and 54.85% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 14.11% and 15.95%, respectively. Additionally, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 85.10.
On January 16th, 2018, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock, with a target price of $200 per share. Wall St. Equities' research coverage also includes the downloadable free report on IDXX at: www.wallstequities.com/registration/?symbol=IDXX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-diagnostic-substances-equities----advanced-accelerator-applications-amag-pharma-dbv-technologies-and-idexx-labs-300590979.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!